Compare MEI & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEI | MDWD |
|---|---|---|
| Founded | 1946 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Electrical Products | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.6M | 212.1M |
| IPO Year | 1994 | 2013 |
| Metric | MEI | MDWD |
|---|---|---|
| Price | $9.07 | $17.14 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $9.00 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 409.0K | 69.7K |
| Earning Date | 03-05-2026 | 05-20-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | ★ 49.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $908,300,000.00 | N/A |
| Revenue This Year | N/A | $48.92 |
| Revenue Next Year | N/A | $35.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.24 | N/A |
| 52 Week Low | $4.88 | $14.90 |
| 52 Week High | $10.24 | $22.51 |
| Indicator | MEI | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 71.49 | 54.56 |
| Support Level | $6.52 | $16.68 |
| Resistance Level | N/A | $18.49 |
| Average True Range (ATR) | 0.49 | 0.58 |
| MACD | 0.14 | -0.01 |
| Stochastic Oscillator | 92.36 | 67.51 |
Methode Electronics Inc supplier of custom-engineered solutions with sales, engineering, and manufacturing locations in North America, Europe, the Middle East, and Asia. It designs, engineers, and produces mechatronic products for Original Equipment Manufacturers (OEMs) utilizing a broad range of technologies for user interface, light-emitting diode (LED) lighting systems, power distribution, and sensor applications. The firm is organized into various business segments: Automotive, Industrial, Interface, and Medical. The Automotive segment, which generates maximum revenue, supplies electronic and electro-mechanical devices and related products to automobiles, including overhead and center consoles, hidden and ergonomic switches, insert molded components, LED-based lighting, and sensors.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.